CY1122460T1 - ΔΙΣΚΙΟ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 7- [4- (4-ΒΕΝΖΟ [b] ΘΕΙΟΦΑΙΝ-4-ΥΛΟ-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΒΟΥΤΟΞΥ]-1Η-ΚΙΙΝΟΛΙΝ-2-ΟΝΗ Ή ΑΛΑΣ ΑΥΤΗΣ - Google Patents

ΔΙΣΚΙΟ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 7- [4- (4-ΒΕΝΖΟ [b] ΘΕΙΟΦΑΙΝ-4-ΥΛΟ-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΒΟΥΤΟΞΥ]-1Η-ΚΙΙΝΟΛΙΝ-2-ΟΝΗ Ή ΑΛΑΣ ΑΥΤΗΣ

Info

Publication number
CY1122460T1
CY1122460T1 CY20201100009T CY201100009T CY1122460T1 CY 1122460 T1 CY1122460 T1 CY 1122460T1 CY 20201100009 T CY20201100009 T CY 20201100009T CY 201100009 T CY201100009 T CY 201100009T CY 1122460 T1 CY1122460 T1 CY 1122460T1
Authority
CY
Cyprus
Prior art keywords
thiophen
piperazin
benzo
butoxy
salt
Prior art date
Application number
CY20201100009T
Other languages
English (en)
Inventor
Yoshiharu Inoue
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48081918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122460(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY1122460T1 publication Critical patent/CY1122460T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Αυτή η εφεύρεση σχετίζεται με ένα δισκίο που περιέχει, ως δραστικό συστατικό, 7-[4-(4-βενζο[b]θειοφαιν-4-υλο-πιπεραζιν-1-υλο) βουτοξυ]-1Η-κινολιν-2-όνη ή ένα άλας αυτής, που έχει εξαιρετική ικανότητα αποσάθρωσης, σταθερότητα αποθήκευσης και φωτοσταθερότητα. Το δισκίο της παρούσας εφεύρεσης που περιλαμβάνει ένα μη επικαλυμμένο δισκίο που περιέχει 7-[4-(4-βενζο[b]θειοφαιν-4-υλο-πιπεραζιν-1-υλο) βουτοξυ]-1Η-κινολιν-2-όνη ή ένα άλας αυτής ως δραστικό συστατικό, έκδοχα όπως λακτόζη, άμυλο αραβοσίτου και μικροκρυσταλλική κυτταρίνη• αποσαθρωτικά όπως χαμηλής υποκατάστασης υδροξυπροπυλοκυτταρίνη, νατριούχο κροσκαρμελλόζη και νατριούχο καρβοξυμεθυλικό άμυλο• συνδετικά υλικά όπως υδροξυπροπυλοκυτταρίνη• λιπαντικά όπως στεατικό• και που περιλαμβάνει επιπλέον μια στιβάδα επικάλυψης που περιέχει υπρομελλόζη• τάλκη• οξείδιο του τιτανίου• χρωστική• και τα παρόμοια, όπου η στιβάδα επικάλυψης εφαρμόζεται στην επιφάνεια του μη επικαλυμμένου δισκίου.
CY20201100009T 2011-10-14 2020-01-08 ΔΙΣΚΙΟ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 7- [4- (4-ΒΕΝΖΟ [b] ΘΕΙΟΦΑΙΝ-4-ΥΛΟ-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΒΟΥΤΟΞΥ]-1Η-ΚΙΙΝΟΛΙΝ-2-ΟΝΗ Ή ΑΛΑΣ ΑΥΤΗΣ CY1122460T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011227057 2011-10-14
PCT/JP2012/076415 WO2013054872A1 (ja) 2011-10-14 2012-10-12 ７－［４－（４－ベンゾ［ｂ］チオフェン－４－イル－ピペラジン－１－イル）ブトキシ］－１Ｈ－キノリン－２－オン又はその塩を含む錠剤

Publications (1)

Publication Number Publication Date
CY1122460T1 true CY1122460T1 (el) 2021-01-27

Family

ID=48081918

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100009T CY1122460T1 (el) 2011-10-14 2020-01-08 ΔΙΣΚΙΟ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 7- [4- (4-ΒΕΝΖΟ [b] ΘΕΙΟΦΑΙΝ-4-ΥΛΟ-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΒΟΥΤΟΞΥ]-1Η-ΚΙΙΝΟΛΙΝ-2-ΟΝΗ Ή ΑΛΑΣ ΑΥΤΗΣ

Country Status (32)

Country Link
US (7) US20140234417A1 (el)
EP (1) EP2767285B1 (el)
JP (2) JP6084161B2 (el)
KR (1) KR102072371B1 (el)
CN (2) CN103889425B (el)
AP (1) AP2014007564A0 (el)
AR (1) AR088319A1 (el)
AU (1) AU2012321723C1 (el)
BR (1) BR112014008603A2 (el)
CA (1) CA2851588C (el)
CL (1) CL2014000909A1 (el)
CO (1) CO6950480A2 (el)
CY (1) CY1122460T1 (el)
DK (1) DK2767285T3 (el)
EA (1) EA032930B1 (el)
ES (1) ES2762479T3 (el)
HR (1) HRP20200037T1 (el)
HU (1) HUE047493T2 (el)
IL (1) IL231513B (el)
IN (1) IN2014DN02055A (el)
JO (1) JO3753B1 (el)
LT (1) LT2767285T (el)
MX (1) MX2014004135A (el)
MY (1) MY173370A (el)
PL (1) PL2767285T3 (el)
PT (1) PT2767285T (el)
SG (2) SG2014013783A (el)
SI (1) SI2767285T1 (el)
TW (1) TWI634908B (el)
UA (1) UA114411C2 (el)
WO (1) WO2013054872A1 (el)
ZA (1) ZA201402333B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP5936732B1 (ja) * 2015-03-05 2016-06-22 日本カラコン合同会社 フィルムコーティング組成物
CN105106142B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
CN106994119A (zh) * 2016-01-22 2017-08-01 浙江华海药业股份有限公司 含有依匹哌唑或其盐的口腔崩解片及其制备方法
WO2017140254A1 (zh) * 2016-02-19 2017-08-24 江苏恒瑞医药股份有限公司 一种含有jak激酶抑制剂或其可药用盐的药物组合物
WO2018003762A1 (ja) * 2016-06-28 2018-01-04 株式会社日本抗菌総合研究所 賦形剤及び錠剤
JP7060878B2 (ja) * 2016-07-27 2022-04-27 日本臓器製薬株式会社 メトトレキサート含有フィルムコーティング錠
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
EP3500249A1 (en) 2016-08-16 2019-06-26 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
CN106496206A (zh) * 2016-08-31 2017-03-15 安徽省润生医药股份有限公司 一种依匹哌唑新的制备方法
US10919898B2 (en) * 2017-02-23 2021-02-16 Boehringer Ingelheim International Gmbh Medical use of compound III
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
EP3545950A1 (en) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmaceutical composition comprising brexpiprazole
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
CN112168794A (zh) * 2020-10-27 2021-01-05 浙江诺得药业有限公司 一种布瑞哌唑片的制备方法
TWI820674B (zh) * 2021-04-13 2023-11-01 大陸商上海雲晟研新生物科技有限公司 布瑞哌唑物口腔薄膜劑、其製備方法及用途
EP4374856A1 (en) 2022-11-23 2024-05-29 Sanovel Ilac Sanayi Ve Ticaret A.S. A process for tablets comprising brexpiprazole

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US20030153617A1 (en) * 2001-12-18 2003-08-14 Dalen Frans Van Simvastatin dosage forms
NZ560368A (en) * 2002-05-03 2008-11-28 Israel Inst Biolog Res Methods and compostions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
EP1648944A1 (en) * 2003-06-09 2006-04-26 The Dow Global Technologies Inc. Stabilized organoborane polymerization initiators and polymerizable compositions
JP2006061067A (ja) * 2004-08-26 2006-03-09 Asahi Kasei Life & Living Corp 酸素インジケーター
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
WO2006097344A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
DE602006004694D1 (de) 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
JP4806595B2 (ja) * 2006-07-05 2011-11-02 富士フイルム株式会社 固体撮像素子駆動装置及びデジタルカメラ
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
EP2132173B1 (en) * 2007-02-26 2015-10-07 Merck Sharp & Dohme Corp. Formulations for cathepsin k inhibitors
TW200900094A (en) * 2007-03-13 2009-01-01 Takeda Pharmaceutical Solid preparation
JP2008308489A (ja) * 2007-05-11 2008-12-25 Santen Pharmaceut Co Ltd ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
CA2701385A1 (en) * 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064
JP5463564B2 (ja) * 2009-05-22 2014-04-09 国立大学法人信州大学 耐熱性及び耐塩性セルラーゼ製剤
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
AR085840A1 (es) 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
CN105709221B (zh) 2011-04-06 2020-11-17 拜欧瓦克西姆有限公司 用于预防和/或治疗人中的hiv疾病的药物组合物
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه

Also Published As

Publication number Publication date
US20210023078A1 (en) 2021-01-28
JP2017088610A (ja) 2017-05-25
IL231513B (en) 2020-01-30
CN103889425A (zh) 2014-06-25
EP2767285A1 (en) 2014-08-20
EA201490783A1 (ru) 2014-07-30
ZA201402333B (en) 2015-07-29
AU2012321723C1 (en) 2017-11-02
CA2851588C (en) 2019-07-02
US20180008600A1 (en) 2018-01-11
PT2767285T (pt) 2020-01-21
ES2762479T3 (es) 2020-05-25
CO6950480A2 (es) 2014-05-20
SG2014013783A (en) 2014-06-27
CA2851588A1 (en) 2013-04-18
JO3753B1 (ar) 2021-01-31
AU2012321723A1 (en) 2014-05-15
IL231513A0 (en) 2014-04-30
US20170165258A1 (en) 2017-06-15
IN2014DN02055A (el) 2015-05-15
HUE047493T2 (hu) 2020-04-28
BR112014008603A2 (pt) 2017-04-18
LT2767285T (lt) 2020-02-10
WO2013054872A1 (ja) 2013-04-18
AP2014007564A0 (en) 2014-04-30
US20190240215A1 (en) 2019-08-08
EP2767285B1 (en) 2019-11-27
NZ622639A (en) 2015-11-27
SI2767285T1 (sl) 2020-03-31
DK2767285T3 (da) 2020-01-27
TW201318651A (zh) 2013-05-16
CN103889425B (zh) 2018-08-03
SG10201608412SA (en) 2016-12-29
US20140234417A1 (en) 2014-08-21
AU2012321723B2 (en) 2017-07-20
KR20140075754A (ko) 2014-06-19
EP2767285A4 (en) 2015-03-11
JPWO2013054872A1 (ja) 2015-03-30
JP6084161B2 (ja) 2017-02-22
KR102072371B1 (ko) 2020-02-03
AR088319A1 (es) 2014-05-28
CN107397730A (zh) 2017-11-28
EA032930B1 (ru) 2019-08-30
PL2767285T3 (pl) 2020-04-30
US10307419B2 (en) 2019-06-04
MY173370A (en) 2020-01-21
UA114411C2 (uk) 2017-06-12
CL2014000909A1 (es) 2014-11-21
MX2014004135A (es) 2014-07-24
US20160158227A1 (en) 2016-06-09
TWI634908B (zh) 2018-09-11
US20220331311A1 (en) 2022-10-20
HRP20200037T1 (hr) 2020-03-20

Similar Documents

Publication Publication Date Title
CY1122460T1 (el) ΔΙΣΚΙΟ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 7- [4- (4-ΒΕΝΖΟ [b] ΘΕΙΟΦΑΙΝ-4-ΥΛΟ-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΒΟΥΤΟΞΥ]-1Η-ΚΙΙΝΟΛΙΝ-2-ΟΝΗ Ή ΑΛΑΣ ΑΥΤΗΣ
PH12020552187A1 (en) Pcsk9 antagonist compounds
AU2011269989A8 (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
PH12019501873A1 (en) Pharmaceutical composition
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
CY1122015T1 (el) Παραγωγο αζολιου βενζολιου
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
CL2011003009A1 (es) Proceso de preparacion de compuestos derivados de 4-fenil-3,5-(tio)piranodionas; compuesto intermediario; y preparacion de dicho intermediario.
WO2011099764A3 (en) Novel pyrimidine derivative for inhibiting the growth of cancer cells
MX2018014813A (es) Composiciones antibacterianas.
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EA201491288A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ БРЕКСПИПРАЗОЛ И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН
PH12019501288A1 (en) Novel preparation containing benzimidazole derivative
FR2941952B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
EP4249072A3 (en) Crystalline forms of quinolone analogs and their salts
CY1120672T1 (el) Παραγωγο πυραζολης
WO2015131814A3 (zh) [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用
TN2014000528A1 (en) Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
JO3641B1 (ar) تركيبة مضادات الفيروسات القهقرية
WO2012014104A3 (en) Composition comprising shellac and/or a salt thereof and sodium starch glycolate
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази
UA41094U (en) Derivatives of 4-(bromomethyl)-2-r-1,3-thiazol-3-ium bromides and 4-bromomethyl-2-r-1,3-thiazoles